Leatt Corp (LEAT) Stock Price & Analysis
Leatt Corp (LEAT) rose 1.99% to USD 12.8 as of June 10, 2026 at 06:02 UTC, according to Nexqual real-time market data.
LEAT last closed at USD 12.55; the session ranged USD 12.75–12.8 on volume of 2,500 shares. Market capitalization is $79.78M, with a 52-week range of USD 8–14.5 (OQB). Source: Nexqual, June 10, 2026 at 06:02 UTC.
Key Statistics (as of June 10, 2026 at 06:02 UTC)
| Price | USD 12.8 |
|---|---|
| Change | ▲ 1.99% (up) |
| Previous Close | USD 12.55 |
| Open | USD 12.75 |
| Day Range | USD 12.75 – 12.8 |
| 52-Week Range | USD 8 – 14.5 |
| Volume | 2,500 shares |
| Market Cap | $79.78M |
| Exchange | OQB |
Technical Analysis (LEAT)
Nexqual's technical model rates LEAT "BUY" based on 5 bullish and 2 bearish signals across 123 daily candles, as of June 10, 2026 at 06:02 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 73.33 (overbought) |
| vs SMA50 | Above (USD 10.62) |
| MACD | 0.54 (positive) |
Analyst Ratings (LEAT)
Wall Street analysts rate LEAT "None", per Nexqual as of June 10, 2026 at 06:02 UTC.
| Consensus Rating | None |
|---|
Earnings (LEAT)
| Next Earnings Date | 2026-08-06 |
|---|
Source: Nexqual, June 10, 2026 at 06:02 UTC.
Financials & Fundamentals (LEAT)
| Total Revenue | $66.05M |
|---|---|
| Revenue Growth (YoY) | +26.90% |
| Gross Margin | +44.02% |
| Operating Margin | +11.88% |
| Profit Margin | +5.92% |
| ROE | +9.37% |
| Debt / Equity | 1.83 |
| Current Ratio | 8.2 |
| Total Cash | $17.01M |
| Total Debt | $803,893 |
| Free Cash Flow | $3.16M |
Source: Nexqual, June 10, 2026 at 06:02 UTC.
Financial Health Score (LEAT)
Nexqual rates Leatt Corp's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 06:02 UTC.
| Growth | Strong — Revenue +27% YoY (latest Q) |
|---|---|
| Profitability | Strong — Gross margin 44%, operating 12% |
| Balance Sheet | Strong — $17M cash, no debt |
| Cash Flow | Mixed — FCF $3M, slim 4.8% margin |
| Efficiency | Mixed — ROE 9%, ROA 6.8% |
Ownership (LEAT)
| Insider Ownership | +44.63% |
|---|---|
| Institutional Ownership | +4.81% |
| Shares Outstanding | 6.23M |
| Float | 3.87M |
Source: Nexqual, June 10, 2026 at 06:02 UTC.
Leadership (LEAT)
Leatt Corp is led by Sean MacDonald C.A., CA (SA) (age 48), CEO, CFO, President & Director, per Nexqual as of June 10, 2026 at 06:02 UTC.
| CEO, CFO, President & Director | Sean MacDonald C.A., CA (SA) (age 48) |
|---|---|
| Founder, Chairman and Research & Development Consultant | Christopher James Leatt ChB, MB (age 57) |
Major Backers & Investors (LEAT)
Notable institutional backers of Leatt Corp include Segall Bryant & Hamill Fundamental International Small Cap Fund, Wynnefield Capital Management LLC, according to Nexqual as of June 10, 2026 at 06:02 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Segall Bryant & Hamill Fundamental International Small Cap Fund | 0.93% |
| Wynnefield Capital Management LLC | 0.16% |
Source: Nexqual, June 10, 2026 at 06:02 UTC.
From Leatt Corp's Latest SEC 10-K Filing (filed 2026-03-24)
Key Strengths & Strategy (as disclosed to the SEC)
- FDA and MHRA registration allow us to take these products directly to market as medical devices for patients (not just athletes) recuperating from injuries, surgery, muscle tears or strains, dislocations, breaks or fractures.
- Both our patents and licensed patented technology allows us to provide a product that cannot easily be duplicated by our competitors.
- While such manufacturing arrangements pose a risk to our ability to safeguard our proprietary technologies and may lead to increased costs, as discussed under the "Risk Factors" heading in this report, we expect that the increase in expected sales volumes will contribute to a lower production cost per unit and that this will translate to better margins for our distributors and retailers. •   Research, Development, Certification and Marketing Capabilities .
Partnerships
- De Villiers shares of preferred stock, we entered into a Settlement Agreement with them, pursuant to which they agreed to release us from any and all liability arising out of or related to our failure to satisfy our prior obligation to them, and we issued 16,800,000 shares of our common stock and 2,400,000 shares of our Series A Preferred Stock to Dr.
- Jarrett in accordance with the agreement, but we did not issue any preferred shares to Dr.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TBTC | Table Trac, Inc. | USD 4.37 | ▼ 2.24% |
| GLXZ | Galaxy Gaming, Inc. | USD 1.8 | ▲ 9.76% |
| WFCF | Where Food Comes From, Inc. | USD 11.02 | ▲ 8.57% |
| FTLF | FitLife Brands, Inc. | USD 10.22 | ▲ 3.55% |
| PRKA | Parks! America, Inc. | USD 37 | ▼ 7.5% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 06:02 UTC. This page is informational and not investment advice.